In phase I/II KRYSTAL-1 trial, the KRASG12C inhibitor adagrasib demonstrated 
encouraging clinical activity against metastatic colorectal cancer, both as a 
monotherapy and when combined with the EGFR inhibitor cetuximab. In patients who 
received adagrasib alone, the disease control rate was 87% and progression-free 
survival was 5.6 months. Among patients who received the drug combination, the 
disease control rate was 100%; data on progression-free survival were immature. 
The findings, along with data on the KRASG12C inhibitor sotorasib, were 
presented at the 2021 European Society for Medical Oncology Congress.